Introduction
Prostate cancer (CaP) is the most common malignant neoplasm to occur in men and the second leading cause of cancer mortality in the United States. 1 The biological aggressiveness of CaP is variable, with a spectrum that ranges from indolent cancer confined to the prostate, to cases with rapid, extra-prostatic extension and distant metastasis. 2, 3 The underlying mechanisms responsible for the clinical progression of CaP are poorly understood, but may involve changes in expression and response to cytokine and growth factor receptors, which can be modulated by inflammatory signals. 4, 5 There is emerging evidence that recurrent or persistent inflammation plays a role in cancer development. [6] [7] [8] Inflammation-mediated events, such as production of reactive oxygen species and activation of growth factors and signal-transduction events that promote cell survival and proliferation, are considered to be components of risk and a factor in cancer progression. 6 This model is supported by the epidemiological relationship between chronic or recurrent local inflammation and cancer development. 6 Examples include the association between Barrett's esophagus and esophageal cancer, Helicobacter gastritis and gastric cancer, chronic pancreatitis and pancreatic cancer, cirrhosis and hepatic cancer, and inflammatory bowel disease and colon carcinoma. 6 Epidemiological studies that examined expression of pro-and anti-inflammatory factors suggested an association between chronic intra-prostatic inflammation and CaP 9, 10 and documented an association between longterm nonsteroidal anti-inflammatory drugs use and reduced CaP risk. 11, 12 Inflammation is frequently present in prostate biopsies, radical prostatectomy specimens and tissue resected for the treatment of benign prostatic hyperplasia, and it is often a feature of atrophic foci characterized by an increased proliferative index. 9 If chronic inflammation is an important factor in CaP development then logical candidate genetic determinants of CaP risk would be allelic variants of genes associated with inflammation. Variants of genes involved in innate and acquired immunity appear to play an important part in determining inherited CaP risk. 13 Macrophage migration inhibitory factor (MIF) is an upstream regulator of innate immunity implicated in tumor growth based on in vitro and murine models of tumorigenesis. 14 The mechanisms underlying MIF's contribution to the malignant phenotype appear diverse, and include promotion of tumor progression by neoangiogenesis, 15 as well as direct enhancement of growth factor-stimulated cell cycle progression by mitogenactivated protein (MAP) kinase activation. 16 MIF also inhibits the pro-apoptotic and growth inhibitory function of the p53 tumor suppressor in neoplastic cell lines. 17 Breast, [18] [19] [20] colon [20] [21] [22] and lung-derived tumors 23, 24 all contain significantly higher levels of MIF mRNA and/or protein than their noncancerous, normal tissue counterparts. Studies also reported MIF expression closely correlated with tumor aggressiveness and metastatic potential. [21] [22] [23] Migration inhibitory factor is produced by prostate epithelial cells in culture, and its secretion is upregulated in metastatic CaP. 25 Associations between high-serum MIF levels or increased intratumor MIF expression, and CaP biologic aggressiveness are reported. 25, 26 Additionally, there is evidence for a relationship between increased MIF expression and the acquisition of drug resistance by hormone-independent CaP cells. 27 Two functional promoter polymorphisms in the 5 0 flanking region of the MIF gene are strongly associated with protein production. The first polymorphism comprises a tetra-nucleotide (CATT) repeat at position À794 of the gene that is present between 5 and 8 times within a Pit-1 transcription factor binding site. 28 Functional gene reporter studies in defined cell lines (for example, monocytes, epithelial cells) demonstrate that MIF gene expression increases proportionally with the number of CATT repeats in the promoter. 28 A second single nucleotide polymorphism (À173G/C) influences MIF gene expression, either by linkage disequilibrium with the CATT site, or by an independent action involving a transcriptional activator site. 29 There is accruing evidence for the clinical relevance of these polymorphisms as high-expression MIF alleles may influence susceptibility and severity of different autoimmune inflammatory disorders. [28] [29] [30] We hypothesized that MIF polymorphisms, which occur commonly in the population, 31 are also associated with incidence and outcome of CaP.
Methods
Approval for this study was obtained from the Bay Pines VA Healthcare System and Yale Institutional Review Boards.
MIF genotyping
A retrospective study of MIF genotype in patients undergoing routine prostate-specific antigen (PSA) screening was performed using random serum samples obtained directly from the Bay Pines Veterans Administration Health Care System (VAHCS) clinical laboratory. At Bay Pines VAHCS all patients are subject to routine PSA screening on an annual basis. The serums were collected the day that they were drawn and stored at À80 1C After the serum sample was obtained individual patient computerized records were searched for all relevant information (PSA, cancer and inflammatory disease diagnosis, Gleason sum, age), which was used to determine if the patient met the appropriate inclusion criteria.
Inclusion criteria for the CaP group (n ¼ 131) were diagnosis of CaP with no other concurrent cancer or inflammatory disease as documented within computerized records, PSA amounts from the randomly obtained serum sample and availability of serum samples for MIF protein, and genotype determinations. Gleason evaluation of prostate biopsies was documented within the computerized records of 77 of the 131 CaP patients. Fiveyear follow-up PSA amounts were available for 42 of the 131 patients. Inclusion criteria for the control group (n ¼ 128) was absence of cancer and/or any inflammatory disease as documented within the individual patient computerized record, PSA amounts from the randomly obtained serum sample and availability of serum samples for MIF protein, and genotype determinations. Controls were enrolled regardless of serum PSA amounts.
Genomic DNA was isolated from serum using DNAzol (Invitrogen, Carlsbad, CA, USA) then amplified by multiple displacement amplification (GenomiPhi, GE Healthcare, Piscataway, NJ, USA). 31 DNA quality was assessed by agarose gel electrophoresis. The yield of amplified genomic DNA was between 10 and 15 mg in a final volume of 50 ml. MIF genotype was determined as described previously. [28] [29] [30] [31] Briefly, PCR for the CATT repeat polymorphism was performed using the forward primer (5 0 -TGCAGGAACCAATACCCATAGG-3 0 ) and a TET fluorescent reverse primer (TET lab5 0 -AATGG TAAACTCGGGGAC-3 0 ) or G/C single nucleotide polymorphism (SNP) regions. 31 The resulting PCR reaction products were denatured and then resolved using an ABI 310 Genetic Analyzer (PerkinElmer-Applied Biosystems, CA, USA). Serum MIF was determined by enzyme-linked immunosorbent assay as described (R&D Systems, Minneapolis, MN, USA). 26 
Statistical analyses
Differences in population characteristics (age, serum MIF and PSA) were analyzed using the Student's t-test or Mann-Whitney U-test, where appropriate. Differences in allele frequencies were analyzed by w 2 -test. Backwards stepwise age-adjusted logistic regression (using SPSS v.14) examined the incidence of CaP associated with MIF polymorphisms and whether these polymorphisms were associated with increased Gleason sum. We examined the effects of single (SNP, CATT) polymorphisms and also of having a combination of these two as there may be a synergistic effect between the SNP and CATT repeats. 32 For the analysis of the combination of MIF polymorphisms on the incidence of CaP and Gleason sum we examined the following three categories: (1) G/G and 5/5, 5/6, 6/6; (2) G/C, C/C or 5/7, 6/7, 7/7; and (3) C/C and 5/7, 6/7, 7/7.
We performed a two-way analysis of variance (ANOVA) to determine the effect of SNP and CATT repeats on MIF serum level. The patients were divided into two categories of SNP: þ C (G/C or C/C) and ÀC (G/G) and two categories of CATT: þ 7 (5/7, 6/7, 7/7) and À7 (5/5, 5/6, 6/6).
We also performed internal cross-validation to estimate the predictive utility of the MIF polymorphisms in determining CaP risk. Using SPSS we randomly divided the data set into a 70% for training a model (using binary logistic regression as above) and 30% for a test of the model to determine specificity (true-positive) and sensitivity (true-negative) estimates. A total of 10 random estimates were averaged to obtain an error of the estimate. In addition, differences in the ability of either polymorphism alone or the combination (SNP/CATT) on specificity and sensitivity were assessed using ANOVA followed by post hoc (Newman-Keuls) tests.
Haplotype frequencies were determined using Phase v2.1.1 (www.stat.washington.edu/stephens/software. html). P-values p0.05 were considered statistically significant in all analyses.
Results

Study population
The demographic characteristics of the CaP patients and the control group are shown in Table 1 33 with the common haplotype distributions varying significantly between the two groups (Po0.0001). The À173G/6-CATT haplotype was the most common haplotype in the control group (44.9%), while the À173C/6-CATT haplotype was the most common in the CaP group (31.4%, Po0.001). Although these results point to a possible difference in the allelic distribution of MIF genotypes in CaP versus control groups, sampling bias is possible because the samples were from a greater than 95% Caucasian veteran population undergoing routine PSA screening. We therefore compared the allelic and genotype frequency of our control and CaP group with that of a previously reported Caucasian control group. 31 The non-Caucasian patients in our group were not included in this analysis because of concerns of racial variation in the population distribution of MIF alleles. 31 There was no difference in the allelic frequency of À173C (P ¼ 0.11) or the À794 CATT (P ¼ 0.09) polymorphisms between our control group and those previously reported for normal Caucasian patients. 28 However, the allelic frequency of the CaP group for both polymorphisms was significantly different from that reported previously for cancer-free Caucasian controls (Po0.0001). 28 MIF À173C and À794 MIF 7-CATT alleles and serum MIF in prostate cancer patients An association between elevated serum MIF levels and CaP was previously reported. 34 In addition, highexpression MIF alleles are associated with higher circulating MIF levels in patients with autoimmune inflammatory arthritis. 29 Therefore, we examined the Table 4 ). Internal cross-validation was used to estimate the predictive utility of the MIF polymorphisms in determining CaP incidence ( Table 5 ). The sensitivity of the combined generated model was 85% with 79.8% accuracy in predicting normal and 72.5% accuracy in predicting CaP patients.
Association between MIF À173C and the À794 MIF 7-CATT polymorphisms and high Gleason sum tumors Migration inhibitory factor circulates in increased concentrations in patients with CaP, and serum levels show a correlation with increasing Gleason sum. 32 The correlation between MIF polymorphisms and CaP histology was determined in tumors with Gleason sum p6 (low grade) and X7 (high grade). Due to the small sample size, the G/C and C/C genotypes were pooled and compared to the G/G genotype and the presence of a single À794 7-CATT allele was compared to its absence. A strong association between high-grade tumors and the À173C allele was determined (OR 9.69, 95% CI 2.20-42.66; Table 6 ). The overall predictive utility of the generated model was 79.2% with 94.7% accuracy in predicting high-grade tumors and 35% accuracy in predicting low-grade tumors. There was no correlation between the presence of a single 7-CATT allele and Gleason sum. In addition, the combination of a single À173C allele and 7-CATT allele was no better at predicting high-grade tumors than the À173C allele alone (Table 6 ). These data suggest that the highexpression À173C MIF genotype closely correlates with CaP aggressiveness. 
Abbreviation: SNP, single-nucleotide polymorphisms. Data are expressed as mean serum MIF amounts7s.e. for each of the SNP and CATT categories. CÀ is defined as G/G, C+ is defined as G/C or C/C; 7À is defined as 5/5, 5/6 or 6/6; 7+ is defined as 5/7, 6/7 or 7/7. Table 4 Age-adjusted OR for the MIF À173 SNP or MIF 5-, 6-,
7-CATT polymorphisms and CaP incidence
Odds ratio (95% CI) P-value Abbreviations: MIF, macrophage migration inhibitory factor; NPV, negative predictive value; PPV, positive predictive value; SNP, single-nucleotide polymorphism. The data are mean percentages of 10 random 70/30 splits of the total data set. Numbers in parentheses are lower and upper limits of 95% CIs.
Prostate cancer recurrence predicted by MIF high-expression polymorphisms The relationship between high-expression MIF polymorphisms and CaP recurrence (biochemical failure defined as two PSA values X0.4 ng ml À1 and rising, or initiation of adjuvant therapy within 5 years post-CaP diagnosis) was examined in 42 of the CaP patients for which repeated PSA determinations were available. We initially grouped these patients into four categories: G/G and 5/5, 5/6 or 6/6 (n ¼ 8), G/C or C/C and 5/5, 5/6 or 6/6 (n ¼ 21), G/G and 5/7, 6/7 or 7/7 (n ¼ 0), and G/C or C/C and 5/7, 6/7 or 7/7 (n ¼ 13). Since there was no recurrence in the G/G and 5/5, 5/6 or 6/6 category, the patients were grouped such that the high-expression MIF alleles (G/C or C/C and 5/7, 6/7 or 7/7, n ¼ 13) were compared to the remaining patients (n ¼ 29). Of the high-MIF expression CaP patients (G/C or C/C and 5/7, 6/7 or 7/7), 46.2% were diagnosed with recurrent cancer within 5 years, whereas only 10.3% of the remaining patients experienced recurrence (OR 4.80, 95% CI 1.20-19.25, P ¼ 0.027; Figure 1 ).
Discussion
We report a significant association between high-production MIF alleles and both incidence and recurrence of CaP. The MIF alleles defined by the À173C SNP and the À794 7-CATT promoter polymorphisms were associated independently with CaP, and this association increased for the À173C/7-CATT haplotype (Table 2 ), in accord with prior observations in autoimmune inflammatory diseases. 29 We also observed a significant association between the À173C/C and À173G/C genotypes with Gleason sum tumors X7 (Table 6 ). An independent contribution of the CATT repeat to Gleason sum was not observed, which may reflect the more significant effect of the À173 SNP or the greater heterogeneity of the CATT locus, which exists in four allelic forms. 27, 28 We also observed a significant association between the presence of the À173C and À794 7-CATT alleles and recurrent cancer within 5 years unrelated to initial Gleason sum (Figure 1 ). This analysis was restricted to Caucasian patients, which comprised the largest ethnic group (495%) within our study population, because of the known population stratification in the MIF locus. 31 Because of limitations in sample size and follow-up clinical data, we could not assess with greater precision the contribution of the different alleles to long-term survival, and such an inquiry will be important to perform.
Both the À173C and the 7-CATT polymorphisms were associated with elevated levels of circulating MIF (Table 3) . These findings support the functional role of these alleles in regulating MIF expression in the studied population, and suggest that MIF's pro-tumorigenic action in prostate tissue may result from either local tissue overexpression or from its action as a circulating mediator. These data are the first evidence supporting the relevance of these polymorphisms in cancer.
Intratumor MIF production has been previously reported to correlate in pathologic studies, with the biological aggressiveness of colon and lung-derived The Gleason sum data were available for a subset of the CaP group (n ¼ 77) that was divided into low (p6) and high (X7) Gleason sum categories. Figure 1 Cox proportional hazard model estimates of remaining free from PSA recurrence based upon migration inhibitory factor (MIF) genotype. Biochemical recurrence (two PSA values of 0.4 ng ml À1 or greater and rising or initiation of adjuvant therapy) was entered into the analysis as the event of interest, and patients not experiencing treatment failure by 60-month post-initial diagnosis were censored based upon the date of last observation. Patients with a À173C/7-CATT carrier genotype had a significantly shorter biochemical recurrence interval than the remaining patients (Po0.01). À173C/7-CATT carrier genotype: 6 events, 7 censored versus remaining genotypes: 3 events, 26 censored.
tumors. [22] [23] [24] MIF expression was observed in premalignant lesions such as colonic tubular adenomas, 35 but it has not, so far, been linked to the earliest steps of carcinogenesis. Several studies identified an association between linked high-expression MIF alleles to different autoimmune inflammatory diseases. [28] [29] [30] The present data are the first evidence supporting the relevance of these polymorphisms in cancer.
Molecular epidemiology studies identified several genetic markers of disease susceptibility for prostatic carcinoma, including genes involved with androgensignaling cascade, vitamin D receptor and those involved in the activation and detoxification of environmental chemicals. 35 The causality and strength of these findings are uncertain because of inconsistency across studies and the relative weakness of the statistical associations. 35 Case-control studies examining genetic polymorphisms in different inflammatory cytokines also have yielded inconsistent results or are biologically difficult to explain. [36] [37] [38] [39] [40] The association of MIF polymorphisms with CaP appears biologically plausible given the observed relationships between high-expression alleles and CaP incidence and outcome, and the correlation with serum MIF levels. Whether MIF has a direct action in carcinogenesis, as suggested by its ability to sustain MAP (ERK-1/2) kinase phosphorylation, 16 and to override p53 tumor suppressor activity, 17, 21, 41 or if it acts primarily to maintain inflammatory cell activation and production of other downstream mediators within the tumor microenvironment, remains to be elucidated. MIF genotype nevertheless may serve as a risk marker in CaP, and therapies directed at MIF, which are presently in clinical development for inflammatory disorders, may offer a useful approach to the treatment of CaP.
